Article(id=1330228493595554540, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228429355593866, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2022.09.009, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1639324800000, receivedDateStr=2021-12-13, revisedDate=1659542400000, revisedDateStr=2022-08-04, acceptedDate=null, acceptedDateStr=null, onlineDate=1795080787323, onlineDateStr=2026-11-19, pubDate=1662739200000, pubDateStr=2022-09-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795080787323, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795080787323, creator=13701087609, updateTime=1795080787323, updator=13701087609, issue=Issue{id=1330228429355593866, tenantId=1146029695717560320, journalId=1319690329412173987, year='2022', volume='43', issue='9', pageStart='1071', pageEnd='1221', issueExtLink='null', onlineDate='null', pubDate='1662739200000', pubDateStr='2022-09-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795080772007, creator='13701087609', updateTime=1795084787841, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330245273550435048, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228429355593866, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330245273550435049, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228429355593866, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1130, endPage=1137, ext={EN=ArticleExt(id=1330228493834629869, articleId=1330228493595554540, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Effectiveness and safety of anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with extensive-stage small cell lung cancer, columnId=1325221089055486019, journalTitle=World Clinical Drug, columnName=Article, runingTitle=null, highlight=null, articleAbstract=
Objective

To investigate the effectiveness and safety of anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

Methods

A total of 40 patients with ES-SCLC who had relapsed after the first-line treatment admitted to Harrison international peace hospital from February 2020 to June 2022 were selected and randomly divided into the observation group and control group, 20 cases in each group. The patients in the control group received hyperthermia chemotherapy with irinotecan and the patients in the observation group were treated with anlotinib based on the control group (took it for 2 weeks and stopped for 1 week). Every 3 weeks was a cycle. The efficacy and adverse reactions of the two groups were compared.

Results

After 2 cycles of chemotherapy, total effective rate for solid tumors, disease control rate of tumors, progression-free survival (PFS) and overall survival (OS) of the observation group were higher than those of the control group (P<0.05). The serum levels of carcinoembryonic antigen, carbohydrate antigen 125, cytokeratin 19 fragment antigen 21-1, pro-gastrin-releasing peptide, neuron-specific enolase of the observation group were higher than those of the control group (P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups during chemotherapy (P>0.05). The serum levels of vascular endothelial growth factor and angiopoietin-2 of the observation group were higher than those of the control group (P<0.05).

Conclusion

Anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with ES-SCLC can improve the short-term efficacy, reduce the level of serum tumor markers, inhibit tumor angiogenesis, prolong PFS and OS, and it is safe and reliable.

, authors=Weiwei WANG, Daqing WANG, Shuangqing CAO*, authorsList=Weiwei WANG, Daqing WANG, Shuangqing CAO, authorCompany=null, correspAuthors=Shuangqing CAO, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330228494149202671, articleId=1330228493595554540, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=安罗替尼联合热化疗用于广泛期小细胞肺癌二线治疗的有效性及安全性, columnId=1325221089235841093, journalTitle=世界临床药物, columnName=研究论文, runingTitle=null, highlight=null, articleAbstract=
目的

观察安罗替尼联合热化疗用于广泛期小细胞肺癌(extensive-stage small cell lung cancer,ES-SCLC)患者二线治疗的有效性及安全性。

方法

选择2020年2月至2022年6月哈励逊国际和平医院收治的经一线治疗后复发的ES-SCLC患者40例,随机分为观察组及对照组,每组20例。对照组接受伊立替康热化疗,观察组在此基础上联合安罗替尼治疗(连服2周,停药1周),每3周为1个周期。比较两组疗效及不良反应。

结果

化疗2个周期后,观察组实体肿瘤总有效率、肿瘤的疾病控制率、无进展生存期(progression-free survival,PFS)及总生存期(overall survival,OS)均高于对照组(P<0.05),观察组血清癌胚抗原、糖类抗原125、细胞角蛋白19片段抗原21-1、胃泌素释放肽前体及神经元特异性烯醇化酶均高于对照组(P<0.05)。两组化疗期间不良反应比较,差异无统计学意义(P>0.05)。观察组血清血管内皮生长因子和血管生成素2均高于对照组(P<0.05)。

结论

安罗替尼联合热化疗用于ES-SCLC患者的二线治疗,可提高近期疗效,降低血清肿瘤标志物水平,抑制肿瘤新生血管生成,延长PFS及OS,安全可靠。

, authors=王薇薇, 王大庆, 曹双清*, authorsList=王薇薇, 王大庆, 曹双清, authorCompany=null, correspAuthors=曹双清, authorNote=

王薇薇,住院医师,研究方向:肿瘤内科诊疗。

, correspAuthorsNote=
曹双清,副主任医师,党委副书记、院长,研究方向:肺部疾病的诊治。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=2n3q9h838GRWhNOJatKkvA==, magXml=1vxmFhH+YqwtRSVA52HoyA==, pdfUrl=null, pdf=/uv5wH/Sbh2h5z2xREpqaA==, pdfFileSize=2599437, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=24+BY8yIcH8l6aN9JFn8Ug==, mapNumber=null, fund=null)}, authors=[Author(id=1330228495797564148, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228495873061622, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, authorId=1330228495797564148, language=EN, stringName=Weiwei WANG, firstName=Weiwei, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228495940170487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, authorId=1330228495797564148, language=CN, stringName=王薇薇, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000, bio={"content":"

王薇薇,住院医师,研究方向:肿瘤内科诊疗。

"}, bioImg=null, bioContent=

王薇薇,住院医师,研究方向:肿瘤内科诊疗。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228495667540720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, xref=null, ext=[AuthorCompanyExt(id=1330228495713678065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China), AuthorCompanyExt(id=1330228495726260978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000)])]), Author(id=1330228496024056570, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228496103748348, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, authorId=1330228496024056570, language=EN, stringName=Daqing WANG, firstName=Daqing, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228496179245821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, authorId=1330228496024056570, language=CN, stringName=王大庆, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228495667540720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, xref=null, ext=[AuthorCompanyExt(id=1330228495713678065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China), AuthorCompanyExt(id=1330228495726260978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000)])]), Author(id=1330228496258937599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330228496338629377, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, authorId=1330228496258937599, language=EN, stringName=Shuangqing CAO, firstName=Shuangqing, middleName=null, lastName=CAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228496418321154, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, authorId=1330228496258937599, language=CN, stringName=曹双清, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228495667540720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, xref=null, ext=[AuthorCompanyExt(id=1330228495713678065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China), AuthorCompanyExt(id=1330228495726260978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000)])])], keywords=[Keyword(id=1330228496523178755, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, language=EN, orderNo=1, keyword=anlotinib), Keyword(id=1330228496586093316, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, language=EN, orderNo=2, keyword=hyperthermia chemotherapy), Keyword(id=1330228496653202181, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, language=EN, orderNo=3, keyword=extensive-stage small cell lung cancer), Keyword(id=1330228496716116742, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, language=EN, orderNo=4, keyword=second-line trestment), Keyword(id=1330228496783225607, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, language=EN, orderNo=5, keyword=clinical efficacy), Keyword(id=1330228496846140168, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, language=EN, orderNo=6, keyword=safety), Keyword(id=1330228496904860425, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, language=CN, orderNo=1, keyword=安罗替尼), Keyword(id=1330228496971969290, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, language=CN, orderNo=2, keyword=热化疗), Keyword(id=1330228497034883852, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, language=CN, orderNo=3, keyword=广泛期小细胞肺癌), Keyword(id=1330228497106187021, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, language=CN, orderNo=4, keyword=二线治疗), Keyword(id=1330228497164907278, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, language=CN, orderNo=5, keyword=临床疗效), Keyword(id=1330228497232016143, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, language=CN, orderNo=6, keyword=安全性)], refs=[Reference(id=1330228497420759825, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Marcoux N, Gettinger SN, O'Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes[J]. J Clin Oncol, 2019, 37(4): 278-285., articleTitle=null, refAbstract=null), Reference(id=1330228497475285778, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=苏月婷, 夏建国, 胡剑峰, 等. 小细胞肺癌的CT分型与影像特征分析[J]. 医学影像学杂志, 2021, 31(2): 351-354., articleTitle=null, refAbstract=null), Reference(id=1330228497538200339, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial[J]. Lancet Oncol, 2016, 17(7): 883-895., articleTitle=null, refAbstract=null), Reference(id=1330228497588531988, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=王芳, 李真, 滕影, 等. 安罗替尼治疗晚期肺癌疗效及短期预后影响因素分析[J]. 安徽医科大学学报, 2021, 56(3): 475-479., articleTitle=null, refAbstract=null), Reference(id=1330228497651446549, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=时景璞. 临床研究中样本量的估计方法[J]. 中国临床康复, 2003, 7(10): 1569-1571., articleTitle=null, refAbstract=null), Reference(id=1330228497714361110, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=刘东雷, 吴恺, 吉浩哲, 等. 血清肿瘤标志物水平及美国东部肿瘤协作组评分在评估非小细胞肺癌根治手术后的预后价值[J]. 中华实验外科杂志, 2019, 36(10): 1896., articleTitle=null, refAbstract=null), Reference(id=1330228497810830103, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=冯奉仪. 实体瘤新的疗效评价标准(解读1.1版RECIST标准)[C]//. 第三届中国肿瘤内科大会论文集, 2009: 123-125., articleTitle=null, refAbstract=null), Reference(id=1330228497928270616, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Kluetz PG, Chingos DT, Basch EM, et al. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J]. Am Soc Clin Oncol Educ Book, 2016, 35: 67-73., articleTitle=null, refAbstract=null), Reference(id=1330228498020545305, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=张爽, 程颖. 小细胞肺癌治疗新进展[J]. 中国肿瘤临床, 2021, 48(10): 501-505., articleTitle=null, refAbstract=null), Reference(id=1330228498133791514, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=王晶, 李凯. 小细胞肺癌治疗中的抗血管生成药物研究进展[J]. 中华肿瘤杂志, 2020, 42(8): 624-628., articleTitle=null, refAbstract=null), Reference(id=1330228498230260507, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=李慧, 刘岩, 柳影, 等. CTLA-4、PD-1和PD-L1在小细胞肺癌外周血中的分布及临床意义[J]. 中国肺癌杂志, 2017, 20(11): 755-760., articleTitle=null, refAbstract=null), Reference(id=1330228498326729500, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=邱鲁鹏, 赵晓, 孙胜杰, 等. PD-1/PD-L1抑制剂治疗复发小细胞肺癌的真实世界研究[J]. 临床肿瘤学杂志, 2021, 26(1): 34-41., articleTitle=null, refAbstract=null), Reference(id=1330228498419004189, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=闻艺璇, 梁利军, 陈婷, 等. 安罗替尼临床应用研究进展[J]. 中华肿瘤防治杂志, 2019, 26(14): 979-985., articleTitle=null, refAbstract=null), Reference(id=1330228500038005535, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=沈娟, 陈雪琴, 马胜林. 安罗替尼抗肿瘤作用研究进展[J]. 浙江医学, 2019, 41(23): 2556-2560., articleTitle=null, refAbstract=null), Reference(id=1330228500109308704, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=康燕, 高景, 宋蒙蒙, 等. 安罗替尼联合顺铂对非小细胞肺癌患者NSE、TGF-β1、MMP-2的影响[J]. 重庆医学, 2021, 50(1): 105-112., articleTitle=null, refAbstract=null), Reference(id=1330228500172223265, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors[J]. J Hematol Oncol, 2016, 9(1): 105., articleTitle=null, refAbstract=null), Reference(id=1330228500235137826, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=杨晓利, 王彩玲, 夏金, 等. 安罗替尼联合紫杉醇和顺铂一线治疗晚期食管鳞癌的疗效分析[J]. 肿瘤防治研究, 2021, 48(7): 719-722., articleTitle=null, refAbstract=null), Reference(id=1330228500293858083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=王乐乐, 白玉勤, 季洪波, 等. 安罗替尼联合依托泊苷二线治疗铂类耐药型晚期卵巢癌的临床研究[J]. 西北国防医学杂志, 2020, 41(6): 361-366., articleTitle=null, refAbstract=null), Reference(id=1330228500373549860, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=梁雪峰, 安玉姬, 张卫华, 等. 广泛期小细胞肺癌一线化疗后安罗替尼维持治疗的临床观察[J]. 临床肿瘤学杂志, 2020, 25(12): 1121-1124., articleTitle=null, refAbstract=null)], funds=[Fund(id=1330228497311707920, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, awardId=2020014062Z, language=CN, fundingSource=衡水市科技计划项目(2020014062Z), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1330228495667540720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, xref=null, ext=[AuthorCompanyExt(id=1330228495713678065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China), AuthorCompanyExt(id=1330228495726260978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.09.009, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.09.009, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2022.09.009, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2022.09.009, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1662739200000, fullTextJson=null, articleText=null, reference=null)
收藏切换
安罗替尼联合热化疗用于广泛期小细胞肺癌二线治疗的有效性及安全性
王薇薇 , 王大庆 , 曹双清 *
世界临床药物 | 研究论文 2022,43(9): 1130-1137
收起
收藏切换
世界临床药物 |研究论文 2022 , 43 (9) : 1130 -1137
安罗替尼联合热化疗用于广泛期小细胞肺癌二线治疗的有效性及安全性
全屏
[Author(id=1330228495797564148, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228495873061622, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, authorId=1330228495797564148, language=EN, stringName=Weiwei WANG, firstName=Weiwei, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228495940170487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, authorId=1330228495797564148, language=CN, stringName=王薇薇, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000, bio={"content":"

王薇薇,住院医师,研究方向:肿瘤内科诊疗。

"}, bioImg=null, bioContent=

王薇薇,住院医师,研究方向:肿瘤内科诊疗。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228495667540720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, xref=null, ext=[AuthorCompanyExt(id=1330228495713678065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China), AuthorCompanyExt(id=1330228495726260978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000)])]), Author(id=1330228496024056570, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228496103748348, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, authorId=1330228496024056570, language=EN, stringName=Daqing WANG, firstName=Daqing, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228496179245821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, authorId=1330228496024056570, language=CN, stringName=王大庆, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228495667540720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, xref=null, ext=[AuthorCompanyExt(id=1330228495713678065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China), AuthorCompanyExt(id=1330228495726260978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000)])]), Author(id=1330228496258937599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330228496338629377, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, authorId=1330228496258937599, language=EN, stringName=Shuangqing CAO, firstName=Shuangqing, middleName=null, lastName=CAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228496418321154, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, authorId=1330228496258937599, language=CN, stringName=曹双清, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228495667540720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, xref=null, ext=[AuthorCompanyExt(id=1330228495713678065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China), AuthorCompanyExt(id=1330228495726260978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228493595554540, companyId=1330228495667540720, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000)])])]
王薇薇, 王大庆, 曹双清*
作者信息
  • 河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000
通讯作者:
曹双清,副主任医师,党委副书记、院长,研究方向:肺部疾病的诊治。
作者简介:

王薇薇,住院医师,研究方向:肿瘤内科诊疗。

Effectiveness and safety of anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with extensive-stage small cell lung cancer
Weiwei WANG, Daqing WANG, Shuangqing CAO*
Affiliations
  • Department of Oncology, Harrison Internatioanal Peace Hospital, Hengshui 053000, Hebei Province, China
出版时间: 2022-09-10 doi: 10.13683/j.wph.2022.09.009
文章导航
收藏切换
目的

观察安罗替尼联合热化疗用于广泛期小细胞肺癌(extensive-stage small cell lung cancer,ES-SCLC)患者二线治疗的有效性及安全性。

方法

选择2020年2月至2022年6月哈励逊国际和平医院收治的经一线治疗后复发的ES-SCLC患者40例,随机分为观察组及对照组,每组20例。对照组接受伊立替康热化疗,观察组在此基础上联合安罗替尼治疗(连服2周,停药1周),每3周为1个周期。比较两组疗效及不良反应。

结果

化疗2个周期后,观察组实体肿瘤总有效率、肿瘤的疾病控制率、无进展生存期(progression-free survival,PFS)及总生存期(overall survival,OS)均高于对照组(P<0.05),观察组血清癌胚抗原、糖类抗原125、细胞角蛋白19片段抗原21-1、胃泌素释放肽前体及神经元特异性烯醇化酶均高于对照组(P<0.05)。两组化疗期间不良反应比较,差异无统计学意义(P>0.05)。观察组血清血管内皮生长因子和血管生成素2均高于对照组(P<0.05)。

结论

安罗替尼联合热化疗用于ES-SCLC患者的二线治疗,可提高近期疗效,降低血清肿瘤标志物水平,抑制肿瘤新生血管生成,延长PFS及OS,安全可靠。

安罗替尼  /  热化疗  /  广泛期小细胞肺癌  /  二线治疗  /  临床疗效  /  安全性
Objective

To investigate the effectiveness and safety of anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

Methods

A total of 40 patients with ES-SCLC who had relapsed after the first-line treatment admitted to Harrison international peace hospital from February 2020 to June 2022 were selected and randomly divided into the observation group and control group, 20 cases in each group. The patients in the control group received hyperthermia chemotherapy with irinotecan and the patients in the observation group were treated with anlotinib based on the control group (took it for 2 weeks and stopped for 1 week). Every 3 weeks was a cycle. The efficacy and adverse reactions of the two groups were compared.

Results

After 2 cycles of chemotherapy, total effective rate for solid tumors, disease control rate of tumors, progression-free survival (PFS) and overall survival (OS) of the observation group were higher than those of the control group (P<0.05). The serum levels of carcinoembryonic antigen, carbohydrate antigen 125, cytokeratin 19 fragment antigen 21-1, pro-gastrin-releasing peptide, neuron-specific enolase of the observation group were higher than those of the control group (P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups during chemotherapy (P>0.05). The serum levels of vascular endothelial growth factor and angiopoietin-2 of the observation group were higher than those of the control group (P<0.05).

Conclusion

Anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with ES-SCLC can improve the short-term efficacy, reduce the level of serum tumor markers, inhibit tumor angiogenesis, prolong PFS and OS, and it is safe and reliable.

anlotinib  /  hyperthermia chemotherapy  /  extensive-stage small cell lung cancer  /  second-line trestment  /  clinical efficacy  /  safety
王薇薇, 王大庆, 曹双清. 安罗替尼联合热化疗用于广泛期小细胞肺癌二线治疗的有效性及安全性. 世界临床药物, 2022 , 43 (9) : 1130 -1137 . DOI: 10.13683/j.wph.2022.09.009
Weiwei WANG, Daqing WANG, Shuangqing CAO. Effectiveness and safety of anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with extensive-stage small cell lung cancer[J]. World Clinical Drug, 2022 , 43 (9) : 1130 -1137 . DOI: 10.13683/j.wph.2022.09.009
  • 衡水市科技计划项目(2020014062Z)
参考文献 引证文献
排序方式:
[1]
Marcoux N, Gettinger SN, O'Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes[J]. J Clin Oncol, 2019, 37(4): 278-285.
[2]
苏月婷, 夏建国, 胡剑峰, 等. 小细胞肺癌的CT分型与影像特征分析[J]. 医学影像学杂志, 2021, 31(2): 351-354.
[3]
Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial[J]. Lancet Oncol, 2016, 17(7): 883-895.
[4]
王芳, 李真, 滕影, 等. 安罗替尼治疗晚期肺癌疗效及短期预后影响因素分析[J]. 安徽医科大学学报, 2021, 56(3): 475-479.
[5]
时景璞. 临床研究中样本量的估计方法[J]. 中国临床康复, 2003, 7(10): 1569-1571.
[6]
刘东雷, 吴恺, 吉浩哲, 等. 血清肿瘤标志物水平及美国东部肿瘤协作组评分在评估非小细胞肺癌根治手术后的预后价值[J]. 中华实验外科杂志, 2019, 36(10): 1896.
[7]
冯奉仪. 实体瘤新的疗效评价标准(解读1.1版RECIST标准)[C]//. 第三届中国肿瘤内科大会论文集, 2009: 123-125.
[8]
Kluetz PG, Chingos DT, Basch EM, et al. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J]. Am Soc Clin Oncol Educ Book, 2016, 35: 67-73.
[9]
张爽, 程颖. 小细胞肺癌治疗新进展[J]. 中国肿瘤临床, 2021, 48(10): 501-505.
[10]
王晶, 李凯. 小细胞肺癌治疗中的抗血管生成药物研究进展[J]. 中华肿瘤杂志, 2020, 42(8): 624-628.
[11]
李慧, 刘岩, 柳影, 等. CTLA-4、PD-1和PD-L1在小细胞肺癌外周血中的分布及临床意义[J]. 中国肺癌杂志, 2017, 20(11): 755-760.
[12]
邱鲁鹏, 赵晓, 孙胜杰, 等. PD-1/PD-L1抑制剂治疗复发小细胞肺癌的真实世界研究[J]. 临床肿瘤学杂志, 2021, 26(1): 34-41.
[13]
闻艺璇, 梁利军, 陈婷, 等. 安罗替尼临床应用研究进展[J]. 中华肿瘤防治杂志, 2019, 26(14): 979-985.
[14]
沈娟, 陈雪琴, 马胜林. 安罗替尼抗肿瘤作用研究进展[J]. 浙江医学, 2019, 41(23): 2556-2560.
[15]
康燕, 高景, 宋蒙蒙, 等. 安罗替尼联合顺铂对非小细胞肺癌患者NSE、TGF-β1、MMP-2的影响[J]. 重庆医学, 2021, 50(1): 105-112.
[16]
Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors[J]. J Hematol Oncol, 2016, 9(1): 105.
[17]
杨晓利, 王彩玲, 夏金, 等. 安罗替尼联合紫杉醇和顺铂一线治疗晚期食管鳞癌的疗效分析[J]. 肿瘤防治研究, 2021, 48(7): 719-722.
[18]
王乐乐, 白玉勤, 季洪波, 等. 安罗替尼联合依托泊苷二线治疗铂类耐药型晚期卵巢癌的临床研究[J]. 西北国防医学杂志, 2020, 41(6): 361-366.
[19]
梁雪峰, 安玉姬, 张卫华, 等. 广泛期小细胞肺癌一线化疗后安罗替尼维持治疗的临床观察[J]. 临床肿瘤学杂志, 2020, 25(12): 1121-1124.
2022年第43卷第9期
7
0
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2022.09.009
  • 接收时间:2021-12-13
  • 首发时间:2026-11-19
  • 出版时间:2022-09-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2021-12-13
  • 修回日期:2022-08-04
基金
衡水市科技计划项目(2020014062Z)
作者信息
    河北省衡水市哈励逊国际和平医院肿瘤内科,河北 衡水 053000

通讯作者:

曹双清,副主任医师,党委副书记、院长,研究方向:肺部疾病的诊治。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.09.009
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏